Literature DB >> 16129514

Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease.

Shirley W Y Tsang1, Mitchell K P Lai, Sara Kirvell, Paul T Francis, Margaret M Esiri, Tony Hope, Christopher P L-H Chen, Peter T-H Wong.   

Abstract

Impaired transmission of acetylcholine-mediated signaling by postsynaptic muscarinic M1 receptors has been postulated to underlie the limited efficacy of cholinergic replacement therapies in Alzheimer's disease (AD). However, a clear relationship between the functionality of M1 receptors and dementia severity has not been demonstrated. The present study aims to measure M1 coupling to its nucleotide binding (G-) protein in the AD neocortex, and to correlate neurochemical findings with clinical features. A cohort of dementia patients was longitudinally assessed for cognitive decline, with postmortem neuropathological confirmation of AD diagnosis. Measures of M1 receptor density, M1/G-protein coupling and choline acetyltransferase (ChAT) activities were performed in the frontal and temporal cortex of 24 AD patients as well as in 12 age-matched controls. We found that M1 receptor densities were unchanged in AD, which contrasted with significantly reduced M1 coupling to G-proteins in severely demented AD patients. Loss of M1/G-protein coupling in the frontal cortex, but not the temporal cortex, also correlated with the rate of cognitive decline. Additionally, correlations between M1/G-protein coupling and ChAT activities were demonstrated in both regions. These results suggest that defective coupling of neocortical M1 receptors to G-proteins is a neurochemical substrate of cognitive decline in AD. Based on its associations with ChAT deficits and dementia severity, we propose that M1/G-protein uncoupling may have a significant role in the disease mechanism of AD and thus may be considered to be a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16129514     DOI: 10.1016/j.neurobiolaging.2005.07.010

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  26 in total

Review 1.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

Review 2.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

3.  Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.

Authors:  Rodrigo Medeiros; Masashi Kitazawa; Antonella Caccamo; David Baglietto-Vargas; Tatiana Estrada-Hernandez; David H Cribbs; Avraham Fisher; Frank M LaFerla
Journal:  Am J Pathol       Date:  2011-06-23       Impact factor: 4.307

4.  Nicotinic and muscarinic agonists and acetylcholinesterase inhibitors stimulate a common pathway to enhance GluN2B-NMDAR responses.

Authors:  Masaru Ishibashi; Yoshihiko Yamazaki; Ricardo Miledi; Katumi Sumikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

5.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease.

Authors:  Pamela E Potter; Paula K Rauschkolb; Yoga Pandya; Lucia I Sue; Marwan N Sabbagh; Douglas G Walker; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2011-05-01       Impact factor: 17.088

6.  Olive oils modulate fatty acid content and signaling protein expression in apolipoprotein E knockout mice brain.

Authors:  Regina Alemany; María A Navarro; Oliver Vögler; Javier S Perona; Jesús Osada; Valentina Ruiz-Gutiérrez
Journal:  Lipids       Date:  2009-11-19       Impact factor: 1.880

7.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

8.  Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology.

Authors:  Mitchell K P Lai; Michelle G K Tan; Sara Kirvell; Carl Hobbs; Jasinda Lee; Margaret M Esiri; Christopher P Chen; Paul T Francis
Journal:  J Neural Transm (Vienna)       Date:  2008-05-28       Impact factor: 3.575

9.  TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects.

Authors:  Yuu Sako; Emi Kurimoto; Takao Mandai; Atsushi Suzuki; Maiko Tanaka; Motohisa Suzuki; Yuji Shimizu; Masami Yamada; Haruhide Kimura
Journal:  Neuropsychopharmacology       Date:  2018-08-01       Impact factor: 7.853

10.  Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis.

Authors:  S W Y Tsang; P T Francis; M M Esiri; P T H Wong; C P L H Chen; M K P Lai
Journal:  Psychopharmacology (Berl)       Date:  2008-03-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.